{
    "nctId": "NCT06578299",
    "briefTitle": "Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer",
    "officialTitle": "The Real World Study of First Line Treatment of HER2 Positive Recurrent/Metastatic Breast Cancer With Inetetamab Combined With Paclitaxel With/Without Pertuzumab\uff08INTPOWER\uff09",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer Stage IV",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 - 70 years, female\n2. Patients with HER2-positive breast cancer defined as immunohistochemical (IHC) test + + +, or FISH test positive\n3. Participants must have histologically or cytologically confirmed invasive breast cancer with locally recurrent inoperable or radiological evidence of metastatic disease\n4. Have not received first-line anti-HER2 treatment or (neo) adjuvant anti-HER2 drug treatment that is effective and has been discontinued for more than 12 months\n5. Patients with assessable target lesion as per RECIST 1.1 and irRECIST criteria;\n6. ECOG PS score 0 or 1, estimated survival time \u22653 months, and can be followed-up;\n7. The cardiopulmonary function is basically normal, with LVEF \u2265 50%;\n8. Adequate organ function;\n9. Female patients of childbearing age who have negative pregnancy tests and voluntarily adopt effective and reliable contraceptive measures\uff1b\n10. The patient voluntarily signs an informed consent form.\n\nExclusion Criteria:\n\n1. Participated in other clinical trials within 4 weeks;\n2. Have received any systematic anti-tumor treatment during the recurrence/metastasis stage (excluding endocrine therapy previously performed for recurrence/metastasis stage);\n3. During the (neo) adjuvant phase, other anti-HER2 treatments were received in addition to trastuzumab and pertuzumab;\n4. Patients who experience disease progression during (neo) adjuvant trastuzumab treatment, as well as patients who experience recurrence/metastasis within 12 months after completing (neo) adjuvant system treatment;\n5. Evidence of central nervous system metastasis or leptomeningeal disease;\n6. Individuals with a known history of allergies to the components of this medication regimen;\n7. Pregnant or lactating women;\n8. Left ventricular ejection fraction\\<50% for cardiac function; Patients with obvious clinical manifestations such as arrhythmia, myocardial ischemia, severe atrioventricular block, heart dysfunction, and severe heart valve disease;\n9. The researchers believe that it is not appropriate to participate in this trial, as any other medical, social, or psychological factors may affect safety or compliance with research procedures.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}